Sarepta Therapeutics (SRPT) stock jumps premarket ahead of Elevidys EMBARK 3-year data
New York, Jan 26, 2026, 05:31 ET — Premarket Sarepta Therapeutics (SRPT.O) climbed about 6.5% to $22.51 in early Monday action. The stock stayed tight, swinging just between $22.51 and $22.57, with roughly 17,600 shares traded, per Public.com data. (Public) The stock surged 9.65% to $23.17 in after-hours trading Friday, fueled by investor bets ahead of Sarepta’s update on its Duchenne muscular dystrophy gene therapy, RTTNews reported. Sarepta plans to unveil three-year “topline” functional data from Part 1 of EMBARK, its global, randomized, placebo-controlled Phase 3 trial of Elevidys in ambulatory kids aged four to seven at treatment, the report